Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review
Diabetic Medicine2021Vol. 39(5), pp. e14741–e14741
Citations Over TimeTop 10% of 2021 papers
Christine Knoll, Sofia Peacock, Mandy Wäldchen, Drew Cooper, Simran Kaur Aulakh, Klemens Raile, Sufyan Hussain, Katarina Braune
Abstract
Commercially developed and open-source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real-world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness.
Related Papers
- → Sensitivity and specificity of dosing alerts for dosing errors among hospitalized pediatric patients(2014)29 cited
- → Efficacy of nivolumab four-weekly dosing schedule based on body weight(2019)10 cited
- → Approaches to maintenance dosing during oral immunotherapy(2022)2 cited
- → The Impact of Role of Pharmacists in Renal Dosage Adjustment Program on Renal Drug Dosing Errors: A Quasi-Experimental Study(2021)1 cited
- → Pharmacokinetics‐Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease(2019)1 cited